expert roundtables by Leonard H. Calabrese, DO; Jonathan Kay, MD; and Vibeke Strand, MD, MACR, FACP
Patients with rheumatoid arthritis (RA) have benefited from a reduction in cardiovascular morbidity in recent decades, but their cardiovascular ris......READ MORE
patient care perspectives by Vibeke Strand, MD, MACR, FACP
Biologic therapy has protective effects on bone loss for patients with rheumatoid arthritis (RA). Patients receiving concomitant osteoporosis thera......READ MORE
expert roundtables by Leonard H. Calabrese, DO; Jonathan Kay, MD; and Vibeke Strand, MD, MACR, FACP
Important differences may exist between rheumatoid arthritis (RA) therapies regarding their impact on immune function and the risk of viral infecti......READ MORE
In certain clinical scenarios, new diagnostic tests such as 14-3-3η protein and multi-biomarker disease activity (MBDA) have been shown to offer ad......READ MORE
patient care perspectives by Jeffrey R. Curtis, MD, MS, MPH
Up to half of individuals with rheumatoid arthritis (RA) cannot or will not take methotrexate (MTX). The appropriate treatment of patients with rel......READ MORE
clinical topic updates by Jeffrey R. Curtis, MD, MS, MPH
While methotrexate (MTX) is considered the foundational drug for the treatment of rheumatoid arthritis (RA) and should be a component of the combin......READ MORE
